Novartis Financial Results - Q3 2025
Novartis announces the company’s financial results for the third quarter of 2025.
Discover our medicines
See how our innovative medicines are addressing society's greatest health challenges.
Commitment to patients
From research and development to expanding access, uncover our commitment to improving people's lives.
Inspired by purpose
Learn about our people and culture, and how we're driven by our mission to reimagine medicine.
Latest News
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
Our Commitment to Manufacturing in the United States
For the first time in our history, Novartis will be able to deliver end-to-end development of its innovative medicines, from R&D to manufacturing, for patients in the US—a milestone that reflects our deep commitment to patients, healthcare systems, and communities.